vs

Side-by-side financial comparison of Bowman Consulting Group Ltd. (BWMN) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Bowman Consulting Group Ltd. is the larger business by last-quarter revenue ($129.0M vs $74.7M, roughly 1.7× Health Catalyst, Inc.). Bowman Consulting Group Ltd. runs the higher net margin — 1.5% vs -121.9%, a 123.4% gap on every dollar of revenue. On growth, Bowman Consulting Group Ltd. posted the faster year-over-year revenue change (13.9% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $8.1M). Over the past eight quarters, Bowman Consulting Group Ltd.'s revenue compounded faster (16.6% CAGR vs -0.0%).

SLR Consulting is a privately owned international sustainability consultancy with offices in Europe, North America, South America, Australasia, and Africa. In 2019, it reported revenues of £150.8 million. Its purpose is ‘Making Sustainability Happen’, which it achieves through its global team of expert advisors and technicians, who partner with clients to tackle some of the world’s most complex sustainability challenges. Its ultimate owner is Solar Holdings Topco Limited.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

BWMN vs HCAT — Head-to-Head

Bigger by revenue
BWMN
BWMN
1.7× larger
BWMN
$129.0M
$74.7M
HCAT
Growing faster (revenue YoY)
BWMN
BWMN
+20.1% gap
BWMN
13.9%
-6.2%
HCAT
Higher net margin
BWMN
BWMN
123.4% more per $
BWMN
1.5%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$1.5M more FCF
HCAT
$9.6M
$8.1M
BWMN
Faster 2-yr revenue CAGR
BWMN
BWMN
Annualised
BWMN
16.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BWMN
BWMN
HCAT
HCAT
Revenue
$129.0M
$74.7M
Net Profit
$2.0M
$-91.0M
Gross Margin
55.0%
Operating Margin
3.2%
-115.3%
Net Margin
1.5%
-121.9%
Revenue YoY
13.9%
-6.2%
Net Profit YoY
-66.7%
-340.3%
EPS (diluted)
$0.13
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BWMN
BWMN
HCAT
HCAT
Q4 25
$129.0M
$74.7M
Q3 25
$126.0M
$76.3M
Q2 25
$122.1M
$80.7M
Q1 25
$112.9M
$79.4M
Q4 24
$113.2M
$79.6M
Q3 24
$113.9M
$76.4M
Q2 24
$104.5M
$75.9M
Q1 24
$94.9M
$74.7M
Net Profit
BWMN
BWMN
HCAT
HCAT
Q4 25
$2.0M
$-91.0M
Q3 25
$6.6M
$-22.2M
Q2 25
$6.0M
$-41.0M
Q1 25
$-1.7M
$-23.7M
Q4 24
$5.9M
$-20.7M
Q3 24
$771.0K
$-14.7M
Q2 24
$-2.1M
$-13.5M
Q1 24
$-1.6M
$-20.6M
Gross Margin
BWMN
BWMN
HCAT
HCAT
Q4 25
55.0%
Q3 25
53.1%
52.6%
Q2 25
53.7%
Q1 25
51.4%
Q4 24
53.2%
Q3 24
52.4%
47.5%
Q2 24
52.5%
Q1 24
50.6%
Operating Margin
BWMN
BWMN
HCAT
HCAT
Q4 25
3.2%
-115.3%
Q3 25
4.2%
-22.9%
Q2 25
7.4%
-46.0%
Q1 25
1.0%
-25.4%
Q4 24
1.2%
-22.0%
Q3 24
0.4%
-17.9%
Q2 24
-1.2%
-20.8%
Q1 24
-2.8%
-30.5%
Net Margin
BWMN
BWMN
HCAT
HCAT
Q4 25
1.5%
-121.9%
Q3 25
5.3%
-29.1%
Q2 25
4.9%
-50.8%
Q1 25
-1.5%
-29.9%
Q4 24
5.2%
-26.0%
Q3 24
0.7%
-19.3%
Q2 24
-2.0%
-17.8%
Q1 24
-1.6%
-27.6%
EPS (diluted)
BWMN
BWMN
HCAT
HCAT
Q4 25
$0.13
$-1.29
Q3 25
$0.37
$-0.32
Q2 25
$0.34
$-0.59
Q1 25
$-0.11
$-0.35
Q4 24
$0.37
$-0.33
Q3 24
$0.04
$-0.24
Q2 24
$-0.13
$-0.23
Q1 24
$-0.11
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BWMN
BWMN
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$11.1M
$95.7M
Total DebtLower is stronger
$57.6M
$153.3M
Stockholders' EquityBook value
$261.1M
$245.8M
Total Assets
$579.7M
$502.6M
Debt / EquityLower = less leverage
0.22×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BWMN
BWMN
HCAT
HCAT
Q4 25
$11.1M
$95.7M
Q3 25
$16.2M
$91.5M
Q2 25
$15.5M
$97.3M
Q1 25
$10.7M
$342.0M
Q4 24
$6.7M
$392.0M
Q3 24
$11.7M
$387.3M
Q2 24
$23.1M
$308.3M
Q1 24
$11.7M
$327.8M
Total Debt
BWMN
BWMN
HCAT
HCAT
Q4 25
$57.6M
$153.3M
Q3 25
$29.8M
$153.1M
Q2 25
$32.0M
$153.0M
Q1 25
$36.4M
$382.9M
Q4 24
$38.1M
$382.4M
Q3 24
$36.4M
$345.0M
Q2 24
$38.8M
Q1 24
$26.8M
Stockholders' Equity
BWMN
BWMN
HCAT
HCAT
Q4 25
$261.1M
$245.8M
Q3 25
$261.8M
$331.9M
Q2 25
$249.6M
$347.5M
Q1 25
$244.1M
$376.8M
Q4 24
$246.1M
$365.2M
Q3 24
$243.2M
$355.0M
Q2 24
$235.6M
$357.0M
Q1 24
$167.3M
$357.2M
Total Assets
BWMN
BWMN
HCAT
HCAT
Q4 25
$579.7M
$502.6M
Q3 25
$510.2M
$587.1M
Q2 25
$538.2M
$616.2M
Q1 25
$528.7M
$891.5M
Q4 24
$505.9M
$858.9M
Q3 24
$497.0M
$813.0M
Q2 24
$463.4M
$691.7M
Q1 24
$420.5M
$695.1M
Debt / Equity
BWMN
BWMN
HCAT
HCAT
Q4 25
0.22×
0.62×
Q3 25
0.11×
0.46×
Q2 25
0.13×
0.44×
Q1 25
0.15×
1.02×
Q4 24
0.15×
1.05×
Q3 24
0.15×
0.97×
Q2 24
0.16×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BWMN
BWMN
HCAT
HCAT
Operating Cash FlowLast quarter
$9.4M
$9.9M
Free Cash FlowOCF − Capex
$8.1M
$9.6M
FCF MarginFCF / Revenue
6.3%
12.9%
Capex IntensityCapex / Revenue
0.9%
0.4%
Cash ConversionOCF / Net Profit
4.76×
TTM Free Cash FlowTrailing 4 quarters
$33.4M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BWMN
BWMN
HCAT
HCAT
Q4 25
$9.4M
$9.9M
Q3 25
$10.2M
$-464.0K
Q2 25
$4.3M
$-9.0M
Q1 25
$12.0M
$280.0K
Q4 24
$11.9M
$-3.5M
Q3 24
$6.8M
$6.2M
Q2 24
$3.1M
$1.6M
Q1 24
$2.5M
$10.3M
Free Cash Flow
BWMN
BWMN
HCAT
HCAT
Q4 25
$8.1M
$9.6M
Q3 25
$10.1M
$-719.0K
Q2 25
$4.2M
$-9.2M
Q1 25
$11.0M
$-390.0K
Q4 24
$11.7M
$-3.9M
Q3 24
$6.6M
$5.5M
Q2 24
$2.7M
$1.3M
Q1 24
$2.3M
$10.1M
FCF Margin
BWMN
BWMN
HCAT
HCAT
Q4 25
6.3%
12.9%
Q3 25
8.0%
-0.9%
Q2 25
3.4%
-11.4%
Q1 25
9.7%
-0.5%
Q4 24
10.4%
-4.9%
Q3 24
5.8%
7.2%
Q2 24
2.6%
1.7%
Q1 24
2.4%
13.5%
Capex Intensity
BWMN
BWMN
HCAT
HCAT
Q4 25
0.9%
0.4%
Q3 25
0.0%
0.3%
Q2 25
0.1%
0.3%
Q1 25
0.9%
0.8%
Q4 24
0.2%
0.5%
Q3 24
0.2%
0.9%
Q2 24
0.3%
0.4%
Q1 24
0.3%
0.3%
Cash Conversion
BWMN
BWMN
HCAT
HCAT
Q4 25
4.76×
Q3 25
1.54×
Q2 25
0.71×
Q1 25
Q4 24
2.02×
Q3 24
8.81×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BWMN
BWMN

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons